Nilvadipine


Full Prescribing Info
Dosage/Direction for Use

Oral
Hypertension
Adult: 4-16 mg/day; reduce dosage to a max of 8 mg in patients with cirrhosis or on cimetidine.

Oral

Cerebrovascular disorders
Adult: 2-4 mg bid

Oral

Angina pectoris
Adult: 8-16 mg/day
Contraindications
Cardiogenic shock, recent MI, unstable angina, severe renal impairment, CHF, aortic stenosis.
Adverse Reactions
Headache, peripheral oedema, dizziness, fatigue, flushing, paradoxical increase in ischaemic chest pain.
Drug Interactions
Increased hypotensive effects with other antihypertensive drugs such as β-blockers, some antipsychotics, ranitidine, and cimetidine.
Food Interaction
Increased bioavailability with grapefruit juice.
Action
Nilvadipine is a dihydropyridine calcium-channel blocker. It is a peripheral and coronary vasodilator, but has little or no effect on cardiac conduction and negative inotropic activity is rarely seen at therapeutic doses. It results in vasodilatation leading to reduced peripheral resistance, BP, and afterload, increased coronary blood flow, and a reflex increase in heart rate. This results in an increase in myocardial oxygen supply and cardiac output.
CIMS Class
ATC Classification
C08CA10 - nilvadipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on nilvadipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in